1 **Molecular surveillance detects high prevalence of the neglected parasite** *Mansonella*

- 2 *ozzardi* **in the Colombian Amazon**
- 3 Dahmer KJ¹, Palma-Cuero M^{1,2}, Ciuoderis K^{2,3}, Patiño C³, Roitman S⁴, Li Z⁴, Sinha A⁴, Hite JL¹,
- 4 Bellido Cuellar O⁵, Hernandez-Ortiz JP^{2,3}, Osorio JE^{1,2}, Christensen BM^{1,2}, Carlow CKS⁴,
- 5 Zamanian $M^{1,2^*}$
- 6 ¹ Department of Pathobiological Sciences, University of Wisconsin-Madison, Madison, WI USA
- ² University of Wisconsin Global Health Institute One Health Colombia, Madison, WI USA
- 3 8 Universidad Nacional de Colombia UW-GHI One Health Colombia, Medellín, Colombia
- 9 ⁴ New England Biolabs, 240 County Road, Ipswich, MA USA
- 10 ⁵ Secretaría de Salud Departamental del Amazonas, Leticia, Colombia
- 11
- 12 Correspondence: mzamanian@wisc.edu

13 Abstract

- 14 Mansonellosis is an undermapped insect-transmitted disease caused by filarial nematodes that
- 15 are estimated to infect hundreds of millions of people globally. Despite their prevalence, there
- 16 are many outstanding questions regarding the general biology and health impacts of the
- 17 responsible parasites. Historical reports suggest that the Colombian Amazon is endemic for
- 18 mansonellosis and may serve as an ideal location to pursue these questions in the backdrop of
- 19 other endemic and emerging pathogens. We deployed molecular and classical diagnostic
- 20 approaches to survey *Mansonella* prevalence among adults belonging to indigenous
- 21 communities along the Amazon River and its tributaries near Leticia, Colombia. Deployment of a
- 22 loop-mediated isothermal amplification (LAMP) assay on blood samples revealed an infection
- 23 prevalence of ~40% for *Mansonella ozzardi*. This assay identified significantly more infections
- 24 than blood smear microscopy or LAMP assays performed using plasma, likely reflecting greater
- 25 sensitivity and the ability to detect low microfilaremias or occult infections. *Mansonella* infection
- 26 rates increased with age and were higher among males compared to females. Genomic
- 27 analysis confirmed the presence of *M. ozzardi* that clusters closely with strains sequenced in
- 28 neighboring countries. We successfully cryopreserved and revitalized *M. ozzardi* microfilariae,
- 29 advancing the prospects of rearing infective larvae in controlled settings. These data suggest an
- 30 underestimation of true mansonellosis prevalence, and we expect that these methods will help
- 31 facilitate the study of mansonellosis in endemic and laboratory settings.
- 32
- 33 Keywords: *Mansonella ozzardi*, epidemiology, loop-mediated isothermal amplification,
- 34 diagnostics, genomics, cryopreservation
- 35 Topic: Colombia, Amazonia, *Mansonella*, infection, infectious disease, *Culicoides*
- 36 Section: Parasitology
- 37
- 38
- 39

40 Introduction

41 Mansonellosis is a highly prevalent but undermapped [1] and understudied parasitic disease 42 that infects hundreds of millions of people throughout Africa and Central and South America [2]. 43 Three species of insect-transmitted parasitic nematodes (*Mansonella ozzardi, M. perstans* and 44 *M. streptocerca*) are responsible for the majority of human cases although other *Mansonella* 45 species have the potential to infect humans, including the recently discovered *Mansonella* sp. 46 "DEUX" which has revitalized demands for allocating resources to study this severely neglected 47 disease [2–5]. 48

49 There are major gaps in our understanding of the basic biology and clinical or subclinical

- 50 impacts of mansonellosis in human populations. *Mansonella* infections underlie variable clinical
- 51 presentations that are likely underrecognized [4] and may alter host immunity in ways that alter
- 52 vaccine responses and susceptibility to other pathogens [6–8]. Drugs used in mass drug
- 53 administration campaigns for lymphatic filariasis and onchocerciasis are not as effective against
- 54 *Mansonella spp.* [9–13] suggesting a unique genetic basis for anthelmintic resistance [14–16].
- 55 Additionally, *Mansonella* infections can introduce diagnostic challenges related to species mis-
- 56 identification [17,18], cross-reactivity of immunochromatographic tests [19,20], and the inability

57 to easily discern occult or amicrofilaremic infections [21]. Together, these limitations can

- 58 potentially confound parasite elimination and surveillance programs focused on more prominent 59 filarial worm parasites in co-endemic regions [9–13,16].
- 60

61 To address these challenges, we deployed both classical and molecular diagnostic approaches 62 to carry out more precise epidemiological surveys of *Mansonella* prevalence in adults from

-
- 63 villages along the Amazon River and its tributaries around the capital city of Leticia in the
- 64 Amazonas Department of Colombia. The Amazon basin is historically associated with "new
- 65 world" *M. ozzardi* [22–25] and is ideally situated to pursue fundamental questions about
- 66 *Mansonella* biology, clinical presentations, and interactions with other pathogens that are
- 67 endemic in the region. Parasite surveys in this region are outdated [22–24], but incidental 68 findings from community health workers in the course of malaria screening and estimates from
- 69 communities in neighboring countries [4,21,26] suggest a high prevalence.
- 70

71 The gold standard diagnostic for *M. perstans* and *M. ozzardi* is blood smear microscopy, which 72 requires morphological differentiation of the circulating microfilariae (mf) stage [4,17]. Molecular 73 diagnostic approaches including real-time PCR (RT-PCR) [27–29] are largely restricted to 74 laboratory settings. However, more recently developed loop-mediated isothermal amplification

- 75 (LAMP) assays with a simple colorimetric readout are more amenable to field studies [30]. We 76 comparatively profiled LAMP assays with classical microscopy-based techniques to evaluate
- 77 potential underestimation of parasite prevalence among a cluster of indigenous communities in
- 78 the Colombian Amazon region. Microfilariae were isolated for population genomic analyses of
- 79 *Mansonella* with respect to previously characterized field isolates, as well as for the
- 80 establishment of a cryopreservation protocol to enable laboratory studies. Lastly, we probed
- 81 associations of *Mansonella* infection status with other clinical and demographic variables. We
- 82 expect that these data and methods will help facilitate future studies of *Mansonella*.

83 Methods

84 Study design and sampling procedure

85 This study was conducted between 2021 and 2023 in the Amazonas Department of Colombia in 86 areas surrounding the capital city of Leticia and Puerto Nariño municipalities (**Figure 1A**). This 87 region of vast biodiversity is largely populated by indigenous communities situated near the 88 Amazon River and its tributaries. The study protocol was reviewed and approved by the UW-89 Madison IRB (study # 2019-1107) and Corporación para Investigaciones Biológicas (CIB 90 #17022021). The study population (n = 235) from 13 communities was recruited by convenience 91 and individuals ≥18 years of age were invited to participate and enrolled after providing written
92 informed consent. Peripheral (venous) blood samples were collected into informed consent. Peripheral (venous) blood samples were collected into 93 ethylenediaminetetraacetic acid (EDTA) tubes and thin and thick blood smears were prepared 94 and examined for the presence of filarial parasites and malaria. Serum/plasma were extracted 95 and aliquoted along with whole blood into 1.5 mL tubes and stored at -80°C for detection of 96 *Mansonella* and other pathogens (**Figure 1B**). Self-reported socio-demographic and 97 epidemiological data were collected using a structured questionnaire through face-to-face 98 interviews at the enrollment site. Recorded data included demographics (age, sex, ethnicity, 99 occupation, place of residence), housing conditions, travel history, medical history (pre-existing 100 diseases), and clinical symptoms. 101

102 **Figure 1**

103 **A)** Map of the study region in the Amazonas Department of Colombia depicting the capital city

- 104 of Leticia and the Puerto Nariño municipality where samples were collected across three
- 105 surveys. The study region is adjacent to the Amazon River at the borders of Colombia, Brazil,
- 106 and Peru. **B)** Schematic of sampling efforts and endpoints for blood samples acquired from
- 107 adult volunteers. Blood smears and preparations of cryopreserved samples were conducted in
- 108 the field. Whole blood was obtained in EDTA tubes and transferred on ice to a laboratory in 109 Leticia. Aliquots of whole-blood and plasma were prepared from samples and used for
- 110 downstream serology, molecular diagnostics, and genomic analyses. Questionnaires were filled
- 111 out at the time of sampling.

112 Microscopy smears and microfilariae quantification

- 113 Routine thin and thick smears were prepared at the time of blood draws. Slides were allowed to
- 114 dry at room temperature, Giemsa stained and examined microscopically. For quantitative
- 115 microscopy, 40 µL of thawed blood was mixed with equal amounts of water and microfilaria (mf)
- 116 were counted using light microscopy. For filtration of thawed blood aliquots, 1 mL of blood
- 117 mixed with 4 ml of phosphate-buffered saline (PBS) was added to a Millipore syringe (Sigma-
- 118 Aldrich, Z268429) with a 5 µm filter membrane (Millipore Sigma, TMTP02500). Filter
- 119 membranes were imprinted in a microscope slide, allowed to dry before methanol fixation and
- 120 Giemsa staining for microscopical observation.

121 Cryopreservation and recovery of microfilariae

- 122 Blood samples were transported on ice from Puerto Nariño to Leticia, where they were mixed
- 123 with 5% dimethyl sulfoxide (DMSO) at a 1:1 ratio, aliquoted in cryogenic tubes and stored at -
- 124 80°C [31]. Processed samples were then shipped to Medellin and stored at -80°C. Samples
- 125 were thawed in a water bath at 37°C for 5 minutes and washed twice with sterile PBS (at 37°C),
- 126 followed by centrifugation at 2,000 rpm for 10 minutes. The mf pellet was gently mixed with 2
- 127 mL of RPMI-1640 + 1x Antibiotic-Antimycotic (Gibco, 15240096). 1 mL aliquots were added to
- 128 wells in a 6-well cell culture plate and the plate was incubated at 37° C and 5% CO₂. Movement
- 129 patterns of mf were recorded using an inverted microscope (40X objective). Movement levels
- 130 were quantified using a customized optical flow pipeline[32].

131 DNA extraction from blood and plasma samples

- 132 DNA was extracted from whole blood and plasma using the Quick-DNA 96-plus kit (Zymo,
- 133 D4070/71) with minor adjustments to the protocol. For blood samples, the "solid tissue protocol"
- 134 was followed by adding 50 µL of blood in place of water and tissue. After incubation for 2.5
- 135 hours, samples were spun at 3,500g for 2 minutes and supernatant lysate was transferred to the
- 136 Zymo-spin 96-XL plate. For plasma samples, the "biological fluid and cells" protocol was
- 137 followed. Final DNA was eluted with 15 µL of water and concentrations were assessed via
- 138 NanoDrop for quality assurance.

139 Loop-mediated isothermal amplification assays

- 140 LAMP reactions were carried out as previously described [30] with slight modifications. Briefly,
- 141 each LAMP reaction contained 1.6 μM each of primers FIP (5'-CGCAAACAGAAGCCCGAAAC-
142 GCTCGCAATTTCATAGTGG-3') and BIP (5'-CTTGCGCGTAGCATTAGATCC-
- 142 GCTCGCAATTTCATAGTGG-3') and BIP (5'-CTTGCGCGTAGCATTAGATCC-
- 143 TCCGAAATGTATACGACAGAT-3'), 0.2 μM each of F3 (5'-GCACGAAATGTTTTTGTACG-3')
144 and B3 (5'-CGTATCACCGTTGATGACG-3'), 0.4 μM each of LF (5'-
- 144 and B3 (5'-CGTATCACCGTTGATGACG-3'), 0.4 μM each of LF (5'-
145 AAGCCTAAGCCTAAGCCTGA-3') and LB (5'-GCACATCTTCAATC
- 145 AAGCCTAAGCCTAAGCCTGA-3') and LB (5'-GCACATCTTCAATCTCCTCTTGC-3'), 2 μl 10X
146 GuHCL, 10 μl of WarmStart Colorimetric LAMP 2x Master Mix (NEB, M1804L), 4 μl water and 2
- 146 GuHCL, 10 μl of WarmStart Colorimetric LAMP 2x Master Mix (NEB, M1804L), 4 μl water and 2
147 Ul of template DNA, or 2 μl water for non-template controls for a total volume of 20 μl per
- 147 μ l of template DNA, or 2 μl water for non-template controls for a total volume of 20 μl per 148 reaction. For a colorimetric readout, reactions were incubated at 63°C for 30 minutes in a
- reaction. For a colorimetric readout, reactions were incubated at 63°C for 30 minutes in a
- 149 SimpliAmp Thermocycler (Applied Biosystems, A24811) and images were acquired using an
- 150 ImageQuant 800 (Cytiva). A post amplification color of yellow indicated detection of *M. ozzardi*,
- 151 and pink (or orange) indicated no detection.
- 152
- 153 For semi-quantitative LAMP (sq-LAMP), simultaneous colorimetric and fluorescent readouts 154 were obtained by adding SYTO™ 9 green (Invitrogen, S34854) to a final concentration of 1 µM 155 in the colorimetric LAMP reaction. Reactions were performed in a Bio-Rad CFX Opus 96 Real-156 Time PCR instrument at 65°C with total fluorescence read in the SYBR/FAM channel every 15 157 seconds for 150 "cycles" (~53 minutes with each "cycle" corresponding to 21.2 seconds of 158 reaction time, 15 seconds combined with plate reading time). A cut-off time threshold (Tt) value 159 of 30 minutes was used to differentiate positive/negative reactions, with Tt defined as the time 160 (min) to reach the fluorescence detection threshold. A Tt ≤ 30 minutes indicated the detection of

It is made available under a CC-BY-NC 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.05.10.23289806;](https://doi.org/10.1101/2023.05.10.23289806) this version posted May 11, 2023. The copyright holder for this preprint

161 the target, whereas a Tt > 30 minutes or N/A, indicated no detection. Plates were scanned using 162 the Epson Perfection v600 Photo Scanner.

163 DNA extraction and Illumina library construction and sequencing

164 DNA was extracted from 200 uL of whole blood using the MagAttract HMW DNA kit (Qiagen, 165 67563) following the manufacturer's instructions. The NEBNext Microbiome DNA enrichment kit 166 (NEB, E2612) was used as directed to enrich *Mansonella* DNA and reduce human DNA prior to 167 library construction. The Illumina libraries were constructed using the NEBNext Ultra II DNA 168 Library Prep Kit for Illumina (NEB, E7645) as described by the manufacturer. The quality and 169 concentration of each library were determined using a 2100 Bioanalyzer with a high-sensitivity 170 DNA chip (Agilent Technologies). Libraries were diluted to 1□nM with 10□mM Tris, 0.1□mM
171 EDTA pH 8. Phi X DNA (5%) was added to balance base pair composition in these A:T rich EDTA pH 8. Phi X DNA (5%) was added to balance base pair composition in these A:T rich 172 filarial libraries prior to sequencing on a NovaSeq platform (paired end, $150 \Box bps$).

173 Bioinformatic analysis

174 Raw Illumina reads were processed to remove adapters and poor-quality reads using the

- 175 BBTools package (https://jgi.doe.gov/data-and-tools/bbtools/). For each isolate, the reads were
- 176 mapped to a combined reference sequence set comprising a *M. ozzardi* reference genome from
- 177 Brazil [16], a reference mitogenome KX822021.1 [33] and the *Wolbachia w*Moz assembly
- 178 GCF_020278625.1 [34] using bowtie2 [35]. Reads mapping to mitochondria were extracted
- 179 from the bam alignment files using samtools [36] and assembled into circular mitochondrial
- 180 genomes using GetOrganelle v1.7.7.0 [37]. The average nucleotide identity scores between
- 181 pairs of all assembled mitogenomes and published mitogenomes, namely the accessions
- 182 KX822021.1 and MN416134.1 for *M. ozzardi* [21,33] and MT361687.1 and MN432521.1 for *M.*
- 183 *perstans* [21,38] were calculated using the OrthoANIu tool [39]. Multiple sequence alignments of
- 184 all *M. ozzardi* and *M. perstans* mitogenomes were obtained using mafft v7.149b [40]. The
- 185 phylogenetic tree based on this alignment was generated using the iqtree online server [41],
- 186 which performs automatic best fit substitution model selection using ModelFinder [42]. Bootstrap
- 187 support values were calculated based on ultrafast bootstrap [43] with 1000 replicates. The tree
- 188 was annotated on the iTOL webserver [44].

189 Serological tests for viral infections

- 190 Serum samples were used for antibody detection against several pathogens. Anti-dengue
- 191 immunoglobulin G (IgG) and IgM were detected using SD BIOLINE Dengue Duo rapid test
- 192 (Abbott), following manufacturer's instructions. Anti-Human Immunodeficiency Virus (HIV),
- 193 Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV) as well as anti-IgM against Severe Acute
- 194 Respiratory Syndrome Coronavirus 2 (SARS-COV-2) were detected by chemiluminescence
- 195 immunoassay using the Architect I1000 system (Abbott), following manufacturer's instructions.

196 Data analysis

197 Self-reported data were recorded on printed surveys by study personnel and completed forms 198 were entered into Microsoft Excel by double entry. Excel spreadsheets were used for data 199 inspection, cleaning, and quality control before data analysis using R Studio software v4.2.2 200 (42). To examine sex- and age-based differences of *M. ozzardi* infections, we used a linear 201 model (lm) to get the residuals and assess the normality of our data. We determined our data 202 did not follow a normal distribution (Shapiro-Wilk test, male age: $W = 0.93224$, p-value = 203 0.0002649 , female age: W = 0.89475, p-value = 8.05e-09). Based on these results, we ran a 204 non-parametric Wilcox rank sum test with a p-value < 0.05 considered statistically significant. 205 Next, to examine differences between infection prevalence across demographic variables and 206 analyses on reported symptoms and serology results, we used generalized linear models 207 (GLMs) with binomial distributions and log link functions [45]. We conducted model selection 208 analyses using the *aictab* function in the R package AICcmodavg [46]. We built candidate 209 models starting with the full model with all combinations of main effects among relevant 210 biological and methodological factors, while avoiding overfitting. We compared candidate 211 models using Akaike's information criterion and Δ AIC (the difference in AIC values for the focal 212 model and the model with the lowest AIC, i.e., the 'winning' model) [47]. We also calculated the model and the model with the lowest AIC, i.e., the 'winning' model) [47]. We also calculated the 213 Akaike weight (w) , which further quantifies the probability that a model is the most appropriate 214 model relative to the candidate models (Supplementary Table 1), AAIC less than two and a 214 model relative to the candidate models (**Supplementary Table 1**). Δ AIC less than two and a
215 higher w generally indicates that a model has substantial support while a suite of best mode 215 bigher w generally indicates that a model has substantial support while a suite of best models 216 in models 216 with low weights ($w \sim 0$) indicates that no single variable plays a substantial role in mediating 217 information changes in the P posterse car [48] we assessed 217 infection dynamics [47]. Using the *Anova* function in the R package car [48], we assessed 218 significance of the effects using Wald χ \square 2 statistics for the winning model.

219 **Supplementary Table 1.** Model selection for prevalence of *M. ozzardi* across demographic 220 variables. Variables include age, sex, education, ethnicity, and location. Global = focal model, $221 \text{ m}8 = \text{winning model}.$

- 222 Protocol and data availability
- 223 All pipelines for statistical analysis and data visualization are available at
- 224 https://github.com/zamanianlab/Mansonella-ms.
- 225
- 226 Raw read data used for assembly of mitogenomes of *M. ozzardi* isolates Moz-Col-195, Moz-
- 227 Col-204, Moz-Col-220 and Moz-Col-239 are submitted under NCBI BioProject XYZ. The
- 228 accession numbers of the assembled mitogenomes are XYZ, XYZ, XYZ, XYZ respectively. The
- 229 mitogenomes of isolates Moz-Brazil-1 and Moz-Venz-1 were assembled from previously
- 230 reported raw read datasets [16] available from NCBI BioProject PRJNA917722 and
- 231 PRJNA917766 respectively. The corresponding GenBank accessions for these mitogenomes
- 232 are XYZ for Moz-Brazil-1 and XYZ for Moz-Venz-1.

233 Results

234 Parasite Prevalence

235 To assess *Mansonella* prevalence within our study population, we deployed a species-specific 236 loop-mediated isothermal amplification (LAMP) assay [30] and compared diagnostic results with 237 microscopic examination of thin blood smears. Across the first survey (samples 1-117), blood 238 LAMP results show a higher prevalence of *M. ozzardi* infections (54/115, 46.9%) than single 239 thin smear microscopy (16/104, 15.3%) and LAMP carried out using DNA from matched plasma 240 (31/115, 26.9%) (**Figure 2 A**)**.** Consensus blood LAMP results were derived from experiments 241 involving DNA extractions from independent aliquots of blood as well as replicates of LAMP 242 assays carried out in two laboratories using DNA from a single extraction (**Supplementary** 243 **Figure 1 A**).

244

245 Treating the blood LAMP as the truth case, thin smear microscopy shows a 31% sensitivity and 246 plasma LAMP shows a 50% sensitivity. For the 30 samples where blood LAMP was positive 247 and microscopy was negative, lower time (Tt) which is indicative of more parasite material being 248 present in semi-quantitative LAMP (sq-LAMP) were observed (**Supplementary Figure 1 B-C**)**.** 249 We therefore hypothesized that the discrepancy between LAMP results and microscopy is likely 250 associated with lower titers of microfilariae in venous blood leading to thin smear false negatives 251 [49] or occult (amicrofilaremic) infections [21] that can only be detected using molecular 252 methods. In both cases, we would expect the blood LAMP assay to display better sensitivity. 253

254 Subsequent surveys (samples 118-186; samples 187-244) were used to probe potential 255 associations between microfilaremia and *Mansonella* diagnostic results by incorporating 256 quantitative microscopy. Blood LAMP assays showed an *M. ozzardi* prevalence of 33% 257 (40/120). Among the 14 samples which tested positive in microscopy, 13 also tested positive in 258 LAMP. Plasma LAMP (16%) and thin smear microscopy detected a lower prevalence (12%), 259 reflecting the pattern observed in the first survey (**Figure 2 B**). Quantitative microscopy detected 260 mf in 23/122 samples (19%), ranging from 0-11 mf/blood spot (**Figure 2 C**). Samples with the 261 highest mf titers were most likely to be positive across blood and plasma LAMP assays and thin 262 smears, while samples with lower mf titers were more likely to be negative in blood smears and 263 only detected in the blood LAMP assay (**Figure 2 D**). This lends support to the hypothesis that 264 low mf titers is a driver of false negatives in both thin smears and plasma LAMP assays. 265

266 To explore whether occult infections could also be a factor contributing to the positive blood 267 LAMP samples which had negative microscopy results, we re-sampled blood from six 268 individuals that fit this pattern. A larger volume of blood (1 mL) was filtered to identify mf that 269 could be circulating at titers not routinely detectable via thick and thin smear microscopy. All six 270 samples were still microscopy negative, supporting the likelihood of occult infections. Whole 271 blood LAMP was the most sensitive diagnostic test and identified a prevalence of 40% for *M.* 272 *ozzardi* across all three surveys (**Table 1**).

- 273
- 274

It is made available under a CC-BY-NC 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.05.10.23289806;](https://doi.org/10.1101/2023.05.10.23289806) this version posted May 11, 2023. The copyright holder for this preprint

275

276 **Figure 2**

277 **A)** Diagnostic results derived from survey one blood samples (1-117) for in-field microscopy 278 smears (M), LAMP using DNA extracted from blood (L_b) , and LAMP using matched DNA 279 extracted from plasma (Lp). **B)** Diagnostic results derived from surveys two and three (samples 280 118-244) for in-field microscopy smears (M), LAMP using DNA extracted from blood (L_h) , and 281 LAMP using matched DNA extracted from plasma (Lp). **C)** Quantitative microscopy counts (qM) 282 derived from surveys two and three blood samples (118-244). **D)** Quantitative microscopy 283 counts of microfilariae stratified by L_b and L_p results and coloured by microscopy smear results. 284 (NN = negative L_b and negative L_p, IN= inconclusive L_b and negative L_p, PN = positive L_b and 285 negative L_p, PP = positive L_b and positive L_p, NP = negative L_b and positive L_p). Grey = negative 286 for *M. ozzardi*; White = no result (A-C). LAMP assay data are specific to *M. ozzardi*.

288 **Supplementary Figure 1**

289 **A)** Diagnostic results derived from survey one blood samples (1-117) for four replicates of 290 LAMP using DNA extracted from blood samples (L_b) across two laboratories. Grey = negative 291 for *M. ozzardi*. White = no result. **B)** Diagnostic results derived from survey one blood samples 292 (1-117) for semi-quantitative LAMP (Tt). ND = not detected **C)** Semi-quantitative LAMP Tt 293 counts (minutes) stratified by L_b and L_b results and colored by thin smear results. Dashed lines 294 indicate Tt cuttoffs (> 1, <30 minutes = positive sq LAMP). (NN = negative L_b and negative L_p, 295 PN = positive L_b and negative L_p , PP = positive L_b and positive L_p , NP = negative L_b and positive 296 Lp). LAMP assay data are specific to *M. ozzardi*.

297

287

298 **Table 1.** Summary and comparison of *M. ozzardi* diagnostic results for the entire study 299 population.

300 Population Demographics

301 The three surveys consisted of individuals who reside in thirteen different communities situated 302 between -02°50'14.9496" north latitude and -03°52'39.1980" south latitude; and - 303 069°44'10.7880" and -070°35'52.2240" west longitude (Figure3 A). A majority of our sampled 304 population were centered in Puerto Nariño (n = 136) (Table 2), where the prevalence of *M.* 305 *ozzardi* as determined by blood LAMP is 44%. The next largest sampled communities in our 306 survey, 12 de Octubre (24%; $n = 25$) and San Pedro de Tipisca (14%; $n = 21$), had lower 307 prevalence. There was a higher prevalence of *M. ozzardi* mf identified via blood LAMP in males 308 $(49\%; n = 84; \text{ mean age} = 40.1 \text{ years})$ compared to females $(32\%; n = 148; \text{ mean age} = 34.7)$ 309 years). The mean age of *M. ozzardi* positive individuals was higher than the mean age of 310 negative individuals in females (Wilcox: $p = 0.026$) but not males (Wilcox: $p = 0.07$) (Figure 3 B). 311 To further examine differences between infection prevalence across demographic variables, we 312 assessed significance of the fixed effects using Wald χ \Box 2 statistics and identified education and 313 place of residence as drivers of prevalence (education binomial GLM: χ \Box 2 = 16.2647, p = 313 place of residence as drivers of prevalence (education binomial GLM: χ 2 = 16.2647, p = 314 0.01240, case origin GLM: χ 2 = 13.6850, p = 0.03336). However, given the limitation of t 314 0.01240, case origin GLM: χ \square 2 = 13.6850, p = 0.03336). However, given the limitation of the 315 data we were unable to confirm significant differences within these groups due to unequal and data we were unable to confirm significant differences within these groups due to unequal and 316 small sample sizes amongst subsets. 317

318 Clinical histories were collected and additional serological tests were carried out for survey two 319 and three samples (n = 117) (**Figure 3 C**) and compared across *M. ozzardi* blood LAMP 320 positive and negative individuals (**Figure 3 D**). Symptoms and serology results that were 321 differentially reported (abdominal pain, fever, joint pain, muscle pain, Hepatitis B antibodies, and 322 Hepatitis C antibodies) between blood LAMP positive and negative individuals were examined 323 further to determine if fixed effects or *M. ozzardi* infections were more likely to explain these 324 data. We assessed significance of the fixed effects and blood LAMP results using Wald $\chi\Box 2$
325 statistics and determined that *M. ozzardi* infection status did not significantly correlate to 325 statistics and determined that *M. ozzardi* infection status did not significantly correlate to 326 reported symptoms or serology results. Fixed effects including sex and age were identified as 327 potential drivers of some of the reported symptoms and serology results but unequal and small

- 328 sample sizes amongst subsets of data limited our post-hoc analysis.
- 329

330 **Figure 3**

331 **A**) A map of the study region in the Amazonas Department of Colombia depicting the

- 332 community where individual participants reside. Point size reflects the number of samples
- 333 collected and color represents the prevalence of *M. ozzardi* infection for each community. **B**) *M.*
- 334 *ozzardi* prevalence as determined by blood LAMP assay stratified by sex and age (95% CI)
- 335 (left) and histogram of *M. ozzardi* prevalence distribution by age (right). F = female, M = male **C**)
- 336 *M. ozzardi* infection status and reported symptoms and serological test results for survey two
- 337 and three individuals ($n = 120$). Orange = positive, present; Grey = negative, not-present; white 338 indicates missing data. **D**) Donut plots reflecting relative fractions of *M. ozzardi* L_b positive and
- 339 L_b negative individuals who self-reported symptoms and lab confirmed serological test results.
- 340

341 **Table 2.** Summary of Demographic and diagnostic data**.** Data includes a subset of the total 342 study population where all summarized demographic information was provided on the

343 questionnaire. (Age in years).

344 Genomic Analysis

345 Whole genome sequencing was performed on 4 samples (ID numbers 195, 204, 220 and 239) 346 which tested positive in the *M. ozzardi* specific blood LAMP assay. Only sample 239 had

- 347 detectable microfilariae in the quantitative microscopy assay. While a mapping analysis of the
- 348 sequencing data showed that over 94% of the reads were from the human host, 1 to 6 % of
- 349 reads mapped to the reference *M. ozzardi* genome assembly and to the *Wolbachia w*Moz
- 350 genome assembly, although at a low coverage (**Supplementary Figure 2**).
- 351
- 352 Sufficient read coverage was obtained for successful assembly of complete, circular
- 353 mitogenomes for each isolate. The assembled mitogenomes displayed more than 99.6%
- 354 sequence identity to each other and to previously reported *M. ozzardi* mitogenomes from Brazil
- 355 [21,33], as well as to the newly assembled mitogenomes from isolates Moz-Brazil-1 and Moz-
- 356 Venz-1 obtained from Brazil and Venezuela respectively [16]. A phylogenetic analysis of all *M.*
- 357 *ozzardi* mitogenomes in conjunction with *M. perstans* mitogenomes from Brazil [21] and
- 358 Cameroon [38] showed a distinct *M. ozzardi* clade with very short branch lengths between
- 359 various isolates and a clear separation from the *M. perstans* clade (**Figure 4**). Together, these
- 360 results confirm the presence of *M. ozzardi* infection in these individuals.

361

362

363 **Figure 4**

364 Maximum-likelihood tree based on whole-mitogenome alignments of various *M. ozzardi* and *M.*

- 365 *perstans* isolates. Abbreviation Moz and Mpe and indicate *M. ozzardi* and *M. perstans*
- 366 respectively. The GenBank accessions are indicated in parenthesis next to isolate names,
- 367 followed by the country of origin in the second parenthesis. Blue colors mark the isolates
- 368 sequenced in this study. The DNA substitution model HKY+F+I was found to be the best fit
- 369 according to Bayesian Information Criteria in ModelFinder. Values of ultrafast bootstrap support
- 370 calculated with 1000 replicates is shown for branches with value higher than 80.
- 371

372 **Supplementary Figure 2**

- 373 **A)** Sequencing read coverage from different *M. ozzardi* isolates on the reference nuclear
- 374 contigs from Moz-Venz-1 genome assembly. **B)** Sequencing read coverage from different *M.*
- 375 *ozzardi* isolates on the *Wolbachia w*Moz reference genome assembly.

376 Cryopreservation of Blood-Dwelling Parasite Stage

377 As a first step towards establishing the lifecycle of *M. ozzardi* in a laboratory environment, we

- 378 sought to functionally cryopreserve microfilariae and observe viable and active worms after
- 379 thawing samples. We collected peripheral blood from individuals who were positive for *M.*
- 380 *ozzardi* via blood LAMP assay and thin smear microscopy in our initial survey. Blood samples
- 381 were mixed with dimethyl sulfoxide (DMSO) and kept at -80°C. We observed revitalization of
- 382 microfilariae upon thawing at 37°C, whereby motility increased over the first 24 hour incubation
- 383 period before steadily declining (**Figure 5 A**). Videos showed viable and healthy microfilariae
- 384 (**Figure 5 B**) that may allow for membrane feeding of lab colonies of *Culicoides* and the
- 385 production of infective-stage larvae (L3) in a laboratory setting.

386 387 **Figure 5**

- 388 **A)** Motility of cryo-preserved *M. ozzardi* microfilariae over 48 hours as measured by an optical
- 389 flow algorithm. **B)** Brightfield images and optical flowmaps of videos used for motility analysis of
- 390 thawed cryopreserved *Mansonella* samples aligned with the timepoints in (A). Brighter regions
- 391 of the flowmaps reflect areas where more parasite movement was detected.

392 Discussion

- 393 We conducted three seroprevalence surveys to better map the distribution of *Mansonella*
- 394 infections among indigenous communities in the Amazon basin of Colombia. Blood smear
- 395 microscopy identified microfilariae in 12.7% of sampled individuals, which falls within the range
- 396 of historical studies in the region [23,24,50]. Blood LAMP assays detected *M. ozzardi* DNA in
- 397 40% of sampled individuals, in closer agreement with more recent PCR-based surveys in the
- 398 Amazon region of neighboring countries [26,28,51,52]. Our survey data adds to the growing
- 399 body of evidence that microscopy-based approaches can drastically underestimate the true
- 400 prevalence of global mansonellosis [5,14,26–30,51–53].

401

402 Molecular diagnostic assays can be leveraged to capture a broader range of infection states, 403 including low microfilaremias or afilaremic (occult) infections [21]. The recovery of complete 404 mitogenomes confirms the presence of *M. ozzardi* DNA in blood samples that previous 405 microscopy diagnostics could not detect, providing further confidence in LAMP diagnostic 406 results. The distribution of *M. ozzardi* adults within the human body is not fully resolved [54], but 407 it is presumed that they commonly take residence in subcutaneous tissues and possibly the 408 serous cavities. These larger stages are the likely source of blood-detectable nucleic acids in 409 molecular diagnostic assays. LAMP assays provide a sensitive, specific, and potentially cost-410 effective approach for the surveillance of filarial nematode infections in human and vector 411 populations [30,55–57]. The development of direct LAMP assays [58] not reliant on DNA 412 extraction will add to the convenience of this approach in endemic settings.

413

414 The establishment of a cryopreservation protocol can facilitate the eventual rearing of *M.* 415 *ozzardi* in laboratory settings, including controlled blood-feeding of reanimated microfilariae to 416 susceptible colonies of biting midges. In vitro phenotyping of *Mansonella* drug responses [59] 417 can help resolve the genetic and molecular basis for observed differences in antifilarial drug 418 susceptibility across species [9,10,12,13,15,60] and open avenues for the screening and

- 419 discovery of new therapeutic leads for mansonellosis.
- 420

421 *Mansonella* is neglected even among neglected pathogens due to a lack of investment in 422 studying its biology and potential health impacts [4,8,61]. More complete demographic and 423 clinical data are needed to determine *M. ozzardi* pathogenicity and assess risk factors. Adult 424 worms disperse somewhat randomly into various tissues and body cavities, the consequences 425 of which can vary considerably across individuals but have historically been summarized as 426 relatively non-pathogenic. Although there are growing clinical case reports suggesting 427 appreciable pathogenicity [4], it is difficult to streamline causal associations with more subtle 428 health impacts. The current established threshold for addressing human filariasis is a causal 429 association with significant morbidity, including blindness and physical disfigurement. 430 Investigation of subclinical or secondary impacts of infection would shift the threshold of 431 potential human clinical concern in mansonellosis-endemic regions to the same threshold that 432 often triggers action as it relates to subclinical nematode infections of livestock and companion 433 animals. We expect that improved diagnostic tools, growing genomic resources, and methods to 434 study *Mansonella* in laboratory settings will facilitate this goal.

435 Acknowledgements

436 The authors thank the communities, the Secretaria de Salud Departamental del Amazonas, 437 Alcaldia de Puerto Nariño, E.S.E Hospital San Rafael de Puerto Nariño, and the Laboratorio

438 Departamental de Salud Pública de Leticia for their contributions to this study. We sincerely

439 thank Julian Rodriguez and Corporacion Corpotropica for their assistance and coordination of

440 activities at the study sites. In addition, we would like to thank the staff of One Health lab and

441 auxiliary personnel at all the study sites for their assistance. Thanks to the Abbott Pandemic

442 Defense Coalition for the provision of laboratory testing kits.

It is made available under a CC-BY-NC 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.05.10.23289806;](https://doi.org/10.1101/2023.05.10.23289806) this version posted May 11, 2023. The copyright holder for this preprint

443 Funding

- 444 KJD was supported by a UW-SciMed GRS Fellowship (scimedgrs.wisc.edu) and NIH
- 445 Parasitology and Vector Biology Training grant number T32 AI007414 (NIH.gov). This work was
- 446 supported by a seed grant from the University of Wisconsin-Madison Global Health Institute
- 447 (GHI) to MZ. CKSC, ZL, AS and SR gratefully acknowledge funding and support from New
- 448 England Biolabs.

449 Conflicts

- 450 CKSC, ZL, AS and SR are employed by New England Biolabs, a manufacturer and vendor of
- 451 molecular biology reagents. This affiliation does not affect the authors' impartiality, adherence to
- 452 journal standards and policies or availability of data. All other authors report no potential 453 conflicts of interest.

454 References

- 455 1. Schluth CG, Standley CJ, Bansal S, Carlson CJ. Spatial parasitology and the unmapped 456 human helminthiases. Parasitology. **2023**; :1–9.
- 457 2. Bélard S, Gehringer C. High Prevalence of Mansonella Species and Parasitic Coinfections 458 in Gabon Calls for an End to the Neglect of Mansonella Research. J Infect Dis. **2021**; 459 223(2):187–188.
- 460 3. Mourembou G, Fenollar F, Lekana-Douki JB, et al. Mansonella, including a Potential New 461 Species, as Common Parasites in Children in Gabon. PLoS Negl Trop Dis. **2015**; 462 9(10):e0004155.
- 463 4. Ta-Tang T-H, Crainey JL, Post RJ, Luz SL, Rubio JM. Mansonellosis: current perspectives. 464 Res Rep Trop Med. **2018**; 9:9–24.
- 465 5. Sandri TL, Kreidenweiss A, Cavallo S, et al. Molecular Epidemiology of Mansonella 466 Species in Gabon. J Infect Dis. **2021**; 223(2):287–296.
- 467 6. Stensgaard A-S, Vounatsou P, Onapa AW, et al. Ecological Drivers of Mansonella perstans 468 Infection in Uganda and Patterns of Co-endemicity with Lymphatic Filariasis and Malaria. 469 PLoS Negl Trop Dis. **2016**; 10(1):e0004319.
- 470 7. Phillips RO, Frimpong M, Sarfo FS, et al. Infection with Mansonella perstans Nematodes in 471 Buruli Ulcer Patients, Ghana. Emerg Infect Dis. **2014**; 20(6):1000–1003.
- 472 8. Ritter M, Ndongmo WPC, Njouendou AJ, et al. Mansonella perstans microfilaremic 473 individuals are characterized by enhanced type 2 helper T and regulatory T and B cell 474 subsets and dampened systemic innate and adaptive immune responses. PLoS Negl Trop 475 Dis. **2018**; 12(1):e0006184.
- 476 9. Bregani ER, Rovellini A, Mbaïdoum N, Magnini MG. Comparison of different anthelminthic 477 drug regimens against Mansonella perstans filariasis. Trans R Soc Trop Med Hyg. **2006**; 478 100(5):458–463.

- 479 10. Van Hoegaerden M, Ivanoff B, Flocard F, Salle A, Chabaud B. The use of mebendazole in 480 the treatment of filariases due to Loa loa and Mansonella perstans. Ann Trop Med 481 Parasitol. **1987**; 81(3):275–282.
- 482 11. Simonsen PE, Onapa AW, Asio SM. Mansonella perstans filariasis in Africa. Acta Trop. 483 **2011**; 120 Suppl 1:S109–20.
- 484 12. Gonzalez AA, Chadee DD, Rawlins SC. Ivermectin treatment of mansonellosis in Trinidad. 485 West Indian Med J. **1999**; 48(4):231–234.
- 486 13. Simonsen PE, Fischer PU, Hoerauf A, Weil G. Manson's Tropical Diseases, 23rd Edition: 487 The Filariases. Manson's Tropical Diseases. unknown; 2014. p. 737–765.
- 488 14. Ta-Tang T-H, Luz SLB, Merino FJ, et al. Atypical Mansonella ozzardi Microfilariae from an 489 Endemic Area of Brazilian Amazonia. Am J Trop Med Hyg. **2016**; 95(3):629–632.
- 490 15. Coulibaly YI, Dembele B, Diallo AA, et al. A randomized trial of doxycycline for Mansonella 491 perstans infection. N Engl J Med. **2009**; 361(15):1448–1458.
- 492 16. Sinha A, Li Z, Poole CB, et al. Genomes of the human filarial parasites Mansonella 493 perstans and Mansonella ozzardi. Frontiers in Tropical Diseases [Internet]. 2023 [cited 494 2023 Apr 3]; 4. Available from: https://doi.org/10.3389/fitd.2023.1139343
- 495 17. Mathison BA, Couturier MR, Pritt BS. Diagnostic Identification and Differentiation of 496 Microfilariae. J Clin Microbiol [Internet]. **2019**; 57(10). Available from: 497 http://dx.doi.org/10.1128/JCM.00706-19
- 498 18. Crainey JL, Bessa Luz SL. Light Microscopic Detection of Mansonella ozzardi 499 Parasitemias. Clin. Infect. Dis. 2019. p. 2156.
- 500 19. Coulibaly YI, Soumaoro L, Dembele B, Hodges M, Zhang Y. POTENTIAL CROSS 501 REACTIVITY OF MANSONELLA PERSTANS WITH WUCHERERIA BANCROFTI BY 502 FILARIASIS TEST STRIPS. AMERICAN JOURNAL OF TROPICAL MEDICINE AND 503 HYGIENE. AMER SOC TROP MED & HYGIENE 8000 WESTPARK DR, STE 130, 504 MCLEAN, VA 22101 USA; 2019. p. 160–160.
- 505 20. Wanji S, Amvongo-Adjia N, Koudou B, et al. Cross-Reactivity of Filariais ICT Cards in 506 Areas of Contrasting Endemicity of Loa loa and Mansonella perstans in Cameroon: 507 Implications for Shrinking of the Lymphatic Filariasis Map in the Central African Region. 508 PLoS Negl Trop Dis. **2015**; 9(11):e0004184.
- 509 21. Crainey JL, Costa CHA, Oliveira Leles LF de, et al. Deep Sequencing Reveals Occult 510 Mansonellosis Coinfections in Residents From the Brazilian Amazon Village of São Gabriel 511 da Cachoeira. Clin Infect Dis. **2020**; 71(8):1990–1993.
- 512 22. Kozek WJ, Palma G, Valencia W, Montalvo C, Spain J. Filariasis in Colombia: prevalence 513 of Mansonella ozzardi in the Departamento de Meta, Intendencia del Casanare, and 514 Comisaría del Vichada. Am J Trop Med Hyg. **1984**; 33(1):70–72.
- 515 23. Lightner LK, Ewert A, Corredor A, Sabogal E. A parasitologic survey for Mansonella ozzardi 516 in the Comisaría del Vaupés, Colombia. Am J Trop Med Hyg. **1980**; 29(1):42–45.
- 517 24. Kozek WJ, D'Alessandro A, Silva J, Navarette SN. Filariasis in Colombia: prevalence of
- 518 mansonellosis in the teenage and adult population of the Colombian bank of the Amazon, 519 Comisaria del Amazonas. Am J Trop Med Hyg. **1982**; 31(6):1131–1136.
- 520 25. Tidwell MA, Tidwell MA. Development of Mansonella ozzardi in Simulium amazonicum, S. 521 argentiscutum, and Culicoides insinuatus from Amazonas, Colombia. Am J Trop Med Hyg. 522 American Society of Tropical Medicine and Hygiene; **1982**; 31(6):1137–1141.
- 523 26. Calvopina M, Chiluisa-Guacho C, Toapanta A, Fonseca D, Villacres I. High Prevalence of 524 Mansonella ozzardi Infection in the Amazon Region, Ecuador. Emerg Infect Dis. **2019**; 525 25(11):2081–2083.
- 526 27. Jiménez M, González LM, Carranza C, et al. Detection and discrimination of Loa loa, 527 Mansonella perstans and Wuchereria bancrofti by PCR-RFLP and nested-PCR of 528 ribosomal DNA ITS1 region. Exp Parasitol. **2011**; 127(1):282–286.
- 529 28. Tang T-HT, López-Vélez R, Lanza M, Shelley AJ, Rubio JM, Luz SLB. Nested PCR to 530 detect and distinguish the sympatric filarial species Onchocerca volvulus, Mansonella 531 ozzardi and Mansonella perstans in the Amazon Region. Mem Inst Oswaldo Cruz. **2010**; 532 105(6):823–828.
- 533 29. Fischer P, Büttner DW, Bamuhiiga J, Williams SA. Detection of the filarial parasite 534 Mansonella streptocerca in skin biopsies by a nested polymerase chain reaction-based
535 assay. Am J Trop Med Hyg. 1998: 58(6):816–820. 535 assay. Am J Trop Med Hyg. **1998**; 58(6):816–820.
- 536 30. Poole CB, Sinha A, Ettwiller L, et al. In Silico Identification of Novel Biomarkers and 537 Development of New Rapid Diagnostic Tests for the Filarial Parasites Mansonella perstans 538 and Mansonella ozzardi. Sci Rep. **2019**; 9(1):10275.
- 539 31. Zinser EW, McTier TL, Kernell NS, Woods DJ. Cryogenic preservation of Dirofilaria immitis 540 microfilariae, reactivation and completion of the life-cycle in the mosquito and vertebrate 541 hosts. Parasit Vectors. **2021**; 14(1):367.
- 542 32. Wheeler NJ, Gallo KJ, Rehborg EJG, Ryan KT, Chan JD, Zamanian M. wrmXpress: A 543 modular package for high-throughput image analysis of parasitic and free-living worms. 544 PLoS Negl Trop Dis. **2022**; 16(11):e0010937.
- 545 33. Crainey JL, Marín MA, Silva TRR da, et al. Mansonella ozzardi mitogenome and 546 pseudogene characterisation provides new perspectives on filarial parasite systematics and 547 CO-1 barcoding. Sci Rep. **2018**; 8(1):6158.
- 548 34. Sinha A, Li Z, Poole CB, et al. Multiple lineages of nematode-Wolbachia symbiosis in 549 supergroup F and convergent loss of bacterioferritin in filarial Wolbachia. Genome Biology 550 and Evolution. 2023; :evad073. Available from: https://doi.org/10.1093/gbe/evad073
- 551 35. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. **2012**; 552 9(4):357–359.
- 553 36. Danecek P, Bonfield JK, Liddle J, et al. Twelve years of SAMtools and BCFtools. 554 Gigascience [Internet]. **2021**; 10(2). Available from: 555 http://dx.doi.org/10.1093/gigascience/giab008
- 556 37. Jin J-J, Yu W-B, Yang J-B, et al. GetOrganelle: a fast and versatile toolkit for accurate de

- 557 novo assembly of organelle genomes. Genome Biol. **2020**; 21(1):241.
- 558 38. Chung M, Aluvathingal J, Bromley RE, et al. Complete Mitochondrial Genome Sequence of 559 Mansonella perstans. Microbiol Resour Announc [Internet]. **2020**; 9(30). Available from: 560 http://dx.doi.org/10.1128/MRA.00490-20
- 561 39. Yoon S-H, Ha S-M, Lim J, Kwon S, Chun J. A large-scale evaluation of algorithms to 562 calculate average nucleotide identity. Antonie Van Leeuwenhoek. **2017**; 110(10):1281– 563 1286.
- 564 40. Nakamura T, Yamada KD, Tomii K, Katoh K. Parallelization of MAFFT for large-scale 565 multiple sequence alignments. Bioinformatics. **2018**; 34(14):2490–2492.
- 566 41. Trifinopoulos J, Nguyen L-T, Haeseler A von, Minh BQ. W-IQ-TREE: a fast online 567 phylogenetic tool for maximum likelihood analysis. Nucleic Acids Res. **2016**; 568 44(W1):W232–5.
- 569 42. Kalyaanamoorthy S, Minh BQ, Wong TKF, Haeseler A von, Jermiin LS. ModelFinder: fast 570 model selection for accurate phylogenetic estimates. Nat Methods. **2017**; 14(6):587–589.
- 571 43. Hoang DT, Chernomor O, Haeseler A von, Minh BQ, Vinh LS. UFBoot2: Improving the 572 Ultrafast Bootstrap Approximation. Mol Biol Evol. **2018**; 35(2):518–522.
- 573 44. Letunic I, Bork P. Interactive Tree Of Life (iTOL) v5: an online tool for phylogenetic tree 574 display and annotation. Nucleic Acids Res. **2021**; 49(W1):W293–W296.
- 575 45. Crawley MJ. The R Book. John Wiley & Sons; 2012.
- 576 46. Mazerolle MJ. AICcmodavg: Model selection and multimodel inference based on (Q)AIC(c) 577 [Internet]. 2023. Available from: https://cran.r-project.org/package=AICcmodavg
- 578 47. Burnham KP, Anderson DR. Model Selection and Inference: A Practical Information-579 Theoretic Approach. Springer New York; 1998.
- 580 48. Fox J, Weisberg S. An R Companion to Applied Regression. SAGE Publications; 2018.
- 581 49. Mischlinger J, Manego RZ, Mombo-Ngoma G, et al. Diagnostic performance of capillary 582 and venous blood samples in the detection of Loa loa and Mansonella perstans 583 microfilaraemia using light microscopy. PLoS Negl Trop Dis. **2021**; 15(8):e0009623.
- 584 50. Shelley AJ. A preliminary survey of the prevalence of Mansonella ozzardi in some rural 585 communities on the river Purus, state of Amazonas, Brazil. Ann Trop Med Parasitol. **1975**; 586 69(3):407–412.
- 587 51. Abrahim CMM, Py-Daniel V, Luz SLB, Fraiji NA, Stefani MMA. Detection of Mansonella 588 ozzardi among blood donors from highly endemic interior cities of Amazonas state, 589 northern Brazil. Transfusion . **2019**; 59(3):1044–1051.
- 590 52. Medeiros JF, Almeida TAP, Silva LBT, et al. A field trial of a PCR-based Mansonella 591 ozzardi diagnosis assay detects high-levels of submicroscopic M. ozzardi infections in both 592 venous blood samples and FTA card dried blood spots. Parasit Vectors. **2015**; 8:280.
- 593 53. Medeiros JF, Fontes G, Nascimento VL do, et al. Sensitivity of diagnostic methods for

- 594 Mansonella ozzardi microfilariae detection in the Brazilian Amazon Region. Mem Inst 595 Oswaldo Cruz. **2018**; 113(3):173–177.
- 596 54. Lima NF, Veggiani Aybar CA, Dantur Juri MJ, Ferreira MU. Mansonella ozzardi: a 597 neglected New World filarial nematode. Pathog Glob Health. **2016**; 110(3):97–107.
- 598 55. Amambo GN, Innocentia N, Abong RA, et al. Application of loop mediated isothermal 599 amplification (LAMP) assays for the detection of Onchocerca volvulus, Loa loa and 600 Mansonella perstans in humans and vectors. Frontiers in Tropical Diseases [Internet]. 601 **2023**; 3. Available from: https://www.frontiersin.org/articles/10.3389/fitd.2022.1016176
- 602 56. Ta-Tang T-H, Berzosa P, Rubio JM, et al. Evaluation of LAMP for the diagnosis of Loa loa 603 infection in dried blood spots compared to PCR-based assays and microscopy. Mem Inst 604 Oswaldo Cruz. **2022**; 116:e210210.
- 605 57. Poole CB, Li Z, Alhassan A, et al. Colorimetric tests for diagnosis of filarial infection and 606 vector surveillance using non-instrumented nucleic acid loop-mediated isothermal
607 monolification (NINA-LAMP). PLoS One. 2017: 12(2):e0169011. 607 amplification (NINA-LAMP). PLoS One. **2017**; 12(2):e0169011.
- 608 58. Avendaño C, Patarroyo MA. Loop-Mediated Isothermal Amplification as Point-of-Care 609 Diagnosis for Neglected Parasitic Infections. Int J Mol Sci [Internet]. **2020**; 21(21). Available 610 from: http://dx.doi.org/10.3390/ijms21217981
- 611 59. Njouendou AJ, Kien CA, Esum ME, et al. In vitro maintenance of Mansonella perstans 612 microfilariae and its relevance for drug screening. Exp Parasitol. **2019**; 206:107769.
- 613 60. Fischer P, Tukesiga E, Büttner DW. Long-term suppression of Mansonella streptocerca
614 microfilariae after treatment with ivermectin. J Infect Dis. 1999: 180(4):1403–1405. 614 microfilariae after treatment with ivermectin. J Infect Dis. **1999**; 180(4):1403–1405.
- 615 61. Metenou S, Babu S, Nutman TB. Impact of filarial infections on coincident intracellular 616 pathogens: Mycobacterium tuberculosis and Plasmodium falciparum. Curr Opin HIV AIDS. 617 **2012**; 7(3):231–238.

A

